This inventor holds 3 USPTO granted patents and 1 published patent application, plus 1 CIPO patent. Top assignee: Q32 Bio Inc.. Active years: 2021-2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2021-2024
Title: Celebrating the Innovations of Kelly C. Fahnoe
Introduction
Kelly C. Fahnoe, based in Waltham, MA, is an acclaimed inventor with a successful track record in the field of biomedical innovations. With three patents to her name, she has made significant contributions to the treatment of complement-mediated diseases. Her groundbreaking work showcases her dedication to advancing medical research and therapy.
Latest Patents
Among her latest patents is a method for treating complement-mediated diseases using fusion protein constructs that comprise an anti-C3d antibody and a complement modulator. This invention provides fusion protein constructs capable of binding to complement-associated antigens, which are crucial in therapeutic applications. Additionally, she holds a patent for another fusion protein construct that includes an anti-C3d antibody and a CR1 polypeptide, further emphasizing her innovative approach to addressing complement mediation conditions.
Career Highlights
Fahnoe is currently associated with Q32 Bio Inc., a company that focuses on developing novel therapies targeting serious diseases. Her work involves advanced protein constructs that have the potential to transform patient care and treatment protocols for complement-mediated diseases. Her commitment to innovation is reflected in her research and patent filings, reinforcing her standing as a notable inventor in her field.
Collaborations
Throughout her career, Kelly has collaborated with several notable individuals, such as Michael Steven Curtis and Michael Storek. These partnerships have enabled her to enhance her research initiatives, broaden her knowledge base, and foster a strong network within the biotechnology industry.
Conclusion
In summary, Kelly C. Fahnoe exemplifies the spirit of innovation through her work on fusion protein constructs aimed at treating complement-mediated diseases. With a firm foundation in scientific research and collaboration, she continues to pave the way for advancements in therapeutic treatments, making a lasting impact on the medical field. Her contributions to Q32 Bio Inc. and her patents reflect her dedication and expertise as a remarkable inventor.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile